Most Likely Diagnosis and Initial Management
Based on the clinical presentation of mid-abdominal cramping pain with heartburn, nausea, and a history of GERD, the most likely diagnosis is GERD with possible functional dyspepsia, and you should initiate a 4-8 week trial of once-daily PPI therapy while implementing lifestyle modifications, particularly smoking cessation. 1
Clinical Reasoning
The symptom constellation points toward an upper gastrointestinal disorder rather than a surgical emergency:
- Mid-epigastric cramping pain that improves with standing (reducing intra-abdominal pressure)
- Heartburn as a cardinal GERD symptom
- Nausea and occasional diarrhea consistent with functional dyspepsia or GERD-related symptoms
- Past GERD diagnosis increases pre-test probability
- Smoking/vaping history is a significant risk factor for GERD exacerbation
The dizziness warrants brief consideration of cardiac causes, but in the context of two days of GI symptoms without chest pain radiation, diaphoresis, or dyspnea, this likely represents vasovagal response to pain/nausea rather than cardiac ischemia.
Initial Treatment Approach
First-Line Therapy
Start single-dose PPI therapy for 4-8 weeks. 1 If inadequate response occurs, escalate to twice-daily dosing or switch to a more effective acid suppressive agent. 1 Once symptoms adequately respond, taper to the lowest effective dose. 1
The 2023 AGA guidelines specifically recommend this empiric approach for patients presenting with troublesome heartburn, regurgitation, and/or non-cardiac chest pain without alarm symptoms. 1
Critical Lifestyle Modifications
Smoking and vaping cessation is non-negotiable - these are major GERD exacerbating factors that will undermine any pharmacologic therapy. 1 Additional modifications include:
- Weight management if applicable
- Avoiding late meals (3+ hours before lying down)
- Head-of-bed elevation
- Avoiding trigger foods (caffeine, alcohol, fatty foods, chocolate, mint)
When to Pursue Diagnostic Testing
Do NOT perform endoscopy or reflux monitoring initially unless alarm features are present. 1 Alarm features requiring immediate endoscopy include:
- Dysphagia or odynophagia
- Unintentional weight loss
- GI bleeding (hematemesis, melena)
- Persistent vomiting
- Palpable mass
- Age >60 with new-onset symptoms (Barrett's screening criteria)
Follow-Up Strategy
If Symptoms Resolve (4-8 weeks)
Taper PPI to lowest effective dose. 1 However, if long-term PPI therapy continues beyond 12 months without objective GERD confirmation, you must offer endoscopy with 96-hour wireless pH monitoring off PPI to establish appropriate long-term use. 1 This is critical to avoid indefinite empiric therapy.
If Symptoms Persist Despite PPI Trial
Perform upper endoscopy. 1 If endoscopy shows no erosive disease (Los Angeles grade B or greater) or Barrett's esophagus, proceed with 96-hour wireless pH monitoring off medication to confirm or exclude GERD. 1
The 2023 guidelines emphasize that 50-60% of patients with suspected GERD symptoms will not have pathologic reflux and will not respond to anti-reflux therapies. 2 Early objective testing prevents prolonged ineffective PPI use.
Endoscopy Findings to Document
Complete evaluation requires: 1
- Erosive esophagitis grading (Los Angeles classification)
- Hiatal hernia presence and axial length
- Hill grade of gastroesophageal flap valve
- Barrett's esophagus screening (Prague classification with biopsy if present)
Alternative Diagnoses if PPI Fails
If reflux testing is negative and symptoms persist, consider:
Functional dyspepsia - characterized by epigastric pain/burning, early satiety, or postprandial fullness without structural explanation. 3 Treatment options include:
- Tricyclic antidepressants (continue 6-12 months if responsive) 3
- Prokinetics (limited availability, side effect concerns) 3
- Psychological therapy for refractory cases 3
Functional abdominal cramping pain - if cramping is the predominant feature, antispasmodics may be beneficial. 4
Common Pitfalls to Avoid
Do not continue empiric PPI indefinitely without objective testing - symptom response may be placebo effect (41-54% specificity for PPI trial). 2
Do not assume PPI response confirms GERD - improvement may result from mechanisms other than acid suppression. 2
Do not ignore the smoking/vaping - this is modifiable and essential for treatment success.
Do not perform upfront testing in typical GERD with heartburn - empiric PPI trial is appropriate first-line. 1 Reserve early testing for isolated extraesophageal symptoms without heartburn. 2
Dizziness requires brief cardiovascular assessment - ensure vital signs are stable and no cardiac risk factors warrant ECG, but don't let this delay GI-directed therapy in this clinical context.